anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
SOLUTION: An extract from leaves of mulberry with water or alcohol is disclosed. The extract has an ICvalue for inhibiting α-glucosidase I at a concentration of less than 90 μg/ml. Preferably, the extract comprises 5-40% (w/w) of total imino sugars and 20-70% (w/w) of total amino acids. The extract is obtained by three extraction and purification steps, and may be used to reduce production of melanin for treatment of such ailments or diseases caused by pigmentation as a freckle, a chloasma, striae gravidarum, a senile plaque and a melanoma. The extract may be used also for controlling a blood glucose level.EFFECT: The extract contains a lower concentration of 1-deoxynojirimycin (DNJ), so that side effects of drugs may be reduced. Since the cost of producing the mulberry extract is much lower than that of producing the pure DNJ compound, the cost of treating hyper-pigmentation caused by ailments is greatly reduced.SELECTED DRAWING: Figure 1
Participants will treated exercises with focused on lower extremities especilly knee joint and muscles. Exercise program continue for 18 sessions with 3 times a week and 6 week duration. Exercises are; straight leg raise, assisted squat, lunge. All sessions supervised by a physiotherapist with synchron tele-rehabilitation.
This is a 17-week study consisting of 4 parts. In Part 1, patients are screened for eligibility. In Part 2 patients undergo approximately 3-weeks of washout from previous phosphate binder therapy. Part 3 of the study is up to 6-week titration period where patients are treated with OLC starting at a dose level of 1500 mg/day. At the end of 2 weeks, the dose will be adjusted based on serum phosphate level, up to a maximum dose of 3000 mg/day. Part 4 of the study is a 4-week Maintenance Period with patients treated for 4 weeks on the clinically effective dose of oxylanthanum carbonate (OLC) identified in the Titration Period. Patients will return to the clinic for the End-of-Study Visit on the last day of the 4-week Maintenance Period before restarting their prescribed phosphate binder therapy. The primary endpoint will be to evaluate the tolerability of OLC (as assessed by rate of discontinuations due to treatment-related adverse events) and the secondary endpoints are the evaluation of the safety of clinically effective doses of OLC and evaluate the pharmacokinetics of OLC. Once weekly, at one of the patient's scheduled dialysis appointments and at the End-of-Study Visit, the tolerability will be assessed. After the End-of-Study Visit, patients will reinitiate standard therapy. Toxicity will be assessed during the study based on the severity grade (mild, moderate, or severe) as assessed by the Investigator.
PURPOSE:An animal drug, obtained by coating the surface of a granular pharmaceutical of an animal drug coated with a hydrophobic waxy material further with a water-soluble polymer, and used for oral administration by mixing in a feed, etc. CONSTITUTION:An animal drug pharmaceutical, obtained by coating an animal drub, e.g. antibiotic, sulfamide agent or nitrofuran based drug, with <=1pts.wt., particularly 5-50pts.wt., based on 100pts.wt. animal drug, hydrophobic waxy material, e.g. higher fatty acid, hardened natural fat or oil or natural wax, and coating the resultant granular pharmaceutical further with a water-soluble polymer, e.g. methyl cellulose, cellulose acetate or gelatin adjusted to preferably 2-5,000cps viscosity, capable of preventing the bitterness of the drug, and readily and orally administrable. If it is difficult to obtain the granular pharmaceutical, a nucleating agent, e.g. mica, talc or kaolin, for promoting crystallization of the animal drug may be incorporated with the hydrophobic waxy material to promote the crystallization.
FIELD: medicine, homeopathy. SUBSTANCE: invention relates to the development of complex homeopathic agents for treatment of patients with influenza and acute respiratory viral infections. The proposed agent has Aconitum C3, Bryonia C3, Atropa belladonna C3, China C3, Baptisia tinctoria C3, Gelsemium sempervirens C3, Allium cepa C3, Echinacea angustifolia C6, Rhus toxicodendron C3 being all components are taken at equal parts. An agent can be made as sugar granules. Treatment with the proposed agent results to the improvement of the general state, complete disappearance of common cold, cough, hoarsenesses (by auscultation test), breathing becomes vesicular, erythrocyte rate precipitation value is normalized, muscle pains are disappeared, appetite and sleep are improved. The total intoxication syndrome is disappeared and respiratory system is recovered completely. EFFECT: enhanced effectiveness of the drug. 2 cl, 1 ex
<P>PROBLEM TO BE SOLVED: To provide a carotinoid-containing emulsion composition being reduced in a smell such as oxidation smell and smell of fish, and also having excellent preservation stability; to provide a method for producing the composition, constituted of simple processes; to provide a food and an external preparation containing the composition; and to provide methods for producing them.  <P>SOLUTION: The carotinoid-containing emulsion composition contains at least the carotenoid, a deoxidized water and a metal-chelating agent. The method for producing the carotenoid-containing emulsion composition includes at least a step for preparing the emulsion by mixing the carotenoid with the deoxidized water and the metal-chelating agent. The food and the external preparation contains the carotenoid-containing emulsion composition. The methods for producing them are also provided.  <P>COPYRIGHT: (C)2008,JPO&INPIT
BACKGROUND: Portal hypertension (PHT) often complicates hepatocellular carcinoma (HCC) treatment and prognosis. We aimed to assess PHT's impact on AtezoBev outcomes and identify predictors of acute variceal bleeding (AVB) and clinical ascites occurrence.
METHODS: A prospective cohort of 200 HCC patients treated with AtezoBev was studied alongside a retrospective cohort of 123 patients treated with Sorafenib. We assessed factors influencing progression-free survival (PFS), overall survival (OS), AVB and clinical ascites development, focusing on PHT parameters, and comparing outcomes within and between the two cohorts (time-dependent Cox model and adjusted survival curves).
RESULTS: Among the AtezoBev cohort, 10% experienced AVB, 24% had high-risk esophageal varices (EV) and 46% vascular invasion. Median PFS and OS in the AtezoBev cohort was 5.13 and 12.2 months. AVB (HR=1.81;[95%CI:1.03-3.17]) and clinical ascites occurrence (HR=2.29;[95%CI:1.52-3.45]) were independently associated with mortality. AVB incidence was 12% at 12 months in AtezoBev patients and EV, history of AVB<6months and vascular invasion were independently associated with AVB. The Sorafenib cohort had shorter median PFS and OS, with similar AVB incidence and only EV were associated with AVB.
CONCLUSIONS: PHT-related events significantly affect not only liver decompensation but also OS in AtezoBev-treated patients. We suggest a more widespread use of NSBB to prevent liver decompensation, with intensified prophylaxis for high-risk patients.
BACKGROUND: Neurofilament light is a blood-based biomarker of neuroaxonal injury that can provide insight into perioperative brain vulnerability and injury. Prior studies have suggested that increased baseline and postoperative concentrations of neurofilament light are associated with delirium after noncardiac surgery, but results are inconsistent. Results have not been reported in cardiac surgery patients, who are among those at highest risk for delirium. We hypothesised that perioperative blood concentrations of neurofilament light (both baseline and change from baseline to postoperative day 1) are associated with delirium after cardiac surgery.
METHODS: This study was nested in a trial of arterial blood pressure targeting during cardiopulmonary bypass using cerebral autoregulation metrics. Blood concentrations of neurofilament light were measured at baseline and on postoperative day 1. The primary outcome was postoperative delirium. Regression models were used to examine the associations between neurofilament light concentration and delirium and delirium severity, adjusting for age, sex, race, logistic European System for Cardiac Operative Risk Evaluation, bypass duration, and cognition.
RESULTS: Delirium occurred in 44.6% of 175 patients. Baseline neurofilament light concentration was higher in delirious than in non-delirious patients (median 20.7 pg ml-1 [IQR 16.1-33.2] vs median 15.5 pg ml-1 [IQR 12.1-24.2], P<0.001). In adjusted models, greater baseline neurofilament light concentration was associated with delirium (odds ratio, 1.027; 95% confidence interval, 1.003-1.053; P=0.029) and delirium severity. From baseline to postoperative day 1, neurofilament light concentration increased by 42%, but there was no association with delirium.
CONCLUSIONS: Baseline neurofilament light concentration, but not change from baseline to postoperative day 1, was associated with delirium after cardiac surgery.
Depression is common in older adults, and antidepressant medication is only effective in about 60% of patients seeking treatment. The purpose of this study is to compare the effectiveness of two different augmentation strategies of antidepressant treatment for depressed older adults who have not responded to an adequate trial of antidepressant medication. The first augmentation strategy is Problem Solving Therapy (PST), a 12-week psychotherapy treatment that has been shown to be effective in depressed older adults. The second augmentation strategy is medication augmentation, which will begin with six weeks of aripiprazole, an atypical antipsychotic medication that has also been shown to be effective in depressed older adults who have failed a trial of antidepressant medication. If patients have not remitted at the end of the 6 week aripiprazole trial, the aripiprazole will be stopped and they will be started on bupropion for the remaining 6 weeks of the study. Both aripiprazole augmentation and bupropion augmentation in depressed older adults have been approved by the FDA. No study has compared the effectiveness of PST and medication augmentation strategies for depressed older adults who are non-responders to an adequate trial of antidepressant medication in the current episode of their depression.
All participants will receive 200 MBq of Cu-64 SARTATE given as a single bolus intravenous injection at Day 0. Participants will receive up to four administrations of Cu-67 SARTATE via a slow intravenous infusion over 30 minutes, 6 to 12 weeks apart. Individual activity administered per cycle will not exceed 5.1 GBq.
ADCY5-related movement disorders are caused by dominant mutations in the ADCY5 gene. This rare neurogenetic disease is characterized by childhood-onset generalized hyperkinetic movements. The abnormal movements typically comprise a combination of dystonia, myoclonus and chorea occurring on a background of axial hypotonia, with superimposed disabling episodes of paroxysmal dyskinesia. The causing mutations are located in the ADCY5 gene coding for the Adenylate Cyclase 5 (AC5). AC5 is highly expressed in the striatal projection neurons of the striatum, a region involved in the control of movements. No effective treatment has been found. Currently, the only tools available to rate the severity of movement disorders observed in ADCY5-patients are clinical rating scales of abnormal movements. These scales use the investigators' judgement to globally rate movements severity in various body parts. This leads to inter-raters' scoring variability. An objective assessment through refined and comprehensive quantification of movements is needed. A motion capture system, such as ViconTM, could better reflect the global and focal variations of abnormal movements. This would be critical for the evaluation of responses to potential treatments. This protocol proposes to investigate a multimodal approach, combining a clinical scale assessment with ViconTM's objective movement measurement. A secondary objective of the study is to assess the effect of coffee on ADCY5-patients. The caffeine contained in coffee acts as a nonselective adenosine receptor antagonist, with a strong affinity for A2A receptors. By blocking A2A receptors, caffeine reduces the enzymatic activity of the altered mutated AC5 protein coded by the mutated ADCY5 gene. This effect could modulate the abnormal movements observed in patients.
The patients in the control group were selected consecutively in the same departments among 1) HIV-infected patients treated with HAART \> 12 months 2) fasting serum LDL cholesterol \> 160 mg/dL 3) without lipid-lowering drugs and one more coronary risk factor. Cases and control patients were matched for age, gender and tobacco consumption.
A dental treatment planning system includes an input form to receive one or more dental patient inputs and an engine adapted to receive dental patient data from the input form and validating the dental patient data in a predetermined sequence. A prospective patient visits the web site on the sental server (280). During an initial examination, the treating professional takes a set of digital facial and intraoral images which is uploaded to the dental server (284). The treating professional generates a dentofacial treatment visualization showing the patient's face and smile before and after treatment (286). Once the patient requests treatment, the treating professional takes impressions and a bite impression and sends it to a company (290). The treating professional creates a separate workspace for the patient, uploads the 'before and after' images into it, and invites the patient to review the image (294).
FIELD: organic chemistry, pharmacy. SUBSTANCE: invention relates to chemistry of heterocyclic compounds showing antagonism with respect to 5-HT 2 -receptors and activity inhibiting reuptake of 5-HT. Invention relates to derivative of morpholine of the formula (I)   where R 1  and R 3  are similar or distinct and each means hydrogen atom or lower alkyl-group; R 2  is halogen atom and dotted line means optionally double bond, or its pharmaceutically acceptable salts, and pharmaceutical composition based on thereof. These compounds can be used for synthesis of antidepressive and sedative drugs. EFFECT: improved method of synthesis. 7 cl, 4 tbl
The first 3 subjects enrolled in the study will receive 5x10\^6 CAR138 T-cells/m\^2 via infusion. The number of cells for the infusion will be increased to 1x10\^7 CAR138 T-cells/m\^2 and then, 2.5x10\^7 CAR138 T-cells/m\^2, 5x10\^7 CAR138 T-cells/m\^2, 1x10\^8 CAR138 T-cells/m\^2 and 2x10\^8 CAR138 T-cells/m\^2 in subsequent cohorts of 3 subjects provided no dose limiting toxicities (DLTs) are observed within 4 weeks of the cell infusion. Cohort enrollment will be staggered, requiring each subject to complete at least 2 weeks of safety monitoring following CAR138 T-cell infusion at the designated dose level for the cohort before another subject is allowed to enroll in the cohort.
1483783 Saponin-containing materials WADLEY RESEARCH INSTITUTE & BLOOD BANK JK AND SUSIE L 24 Oct 1974 [10 Dec 1973] 46042 74 Heading A5B [Also in Division C2] Haemolytic saponin-containing material which has been extracted from plant tissue is detoxified by separating from an aqueous solution thereof constituents which are toxic to microbial organisms and which have an apparent mol. wt. in said solution of up to 600. Preferably there is used a gel or a filter membrane of mean pore diameter 11-24 which passes the toxins but retains the saponins. An ultrafiltration apparatus for this is described and illustrated. The solvent for the aqueous solution may be distilled water or normal saline solution. Specified saponin sources are soap bark (Quillaja Saponaria), soap berry, panama wool and licquorice. Saponins mentioned are glycosides of diosgenin and of quillaic acid. The purified saponin is used to haemolyse red blood cells in a blood sample which may then be subjected to a bacteria cultering process.
This three-year study will be divided into two phases. Phase I will be devoted to developing and refining an instrument, the Pre-PeCKS, into a valid and reliable data gathering observational tool. In Phase II the Pre-PeCKS will be used to develop a predictive model that can discriminate between those with and without MSD-UE. The model developed will be used to select the construction and weighting of the subscales of the final instrument, the PeCKS. The specific aim of Phase I is to evaluate the inter- and intra- rater reliability and the concurrent criterion-related validity of the Pre-PeCKS; the specific aim of Phase II is to use information gathered using the Pre-PeCKS to develop a diagnostic instrument that can identify those with and without MSD-UE. In Phase I, 50 subjects will be digitally recorded while typing while at the same time the kinematics of their hands will be recorded using a VICON™ motion analysis system and a keyboard force plate. The video of the typing performance will be rated by independent raters using the Pre-PeCKS and reliability statistics will be calculated. Concurrent validity will be obtained by comparing the results of the VICON™ with the results of the Pre-PeCKS. In Phase II, 20 typists with MSD-UE and 20 typists without MSD-UE will be rated using the Pre-PeCKS. Variables from the Pre-PeCKS along with other variables of interest will be used to build models that can discriminate between those with and without MSD-UE. The best model will be used to assign weights to Pre-PeCKS parameters and to develop how subscores will be combined to best identify those with MSD-UE. This information will be integrated into the final tool, the PeCKS. The PeCKS can then be used to identify an individual who have keyboarding styles that have been associated with MSD-UE.
An apparatus and method is provided for healing and regeneration of live human and animal bodies and influencing interaction and intercommunication at the cellular level. The apparatus can include one or more environmental and/or body sensors. An electrical circuit can also be provided to produce a square or trapezoidal wave that is delivered to a transducer for application, preferably timed at specific frequencies Delta, Theta, Alpha, to Beta, based on information received from the one or more sensors. In certain embodiments, a DC power source can be provided which allows the apparatus to be portable. A wireless communication module can also be provided. An apparatus and method for structuring water is also disclosed.
The KD children will be randomly assigned to three groups. The patients in group B will receive IVIG 1g/kg for 2 days continuousl.
Poor glycemic control is associated with increased risk of diabetes-related complications in persons with type 1 diabetes (T1D). Despite advancements in insulin therapies and an increase in diabetes technology use, only 21% of adults with T1D are meeting their targeted glycated hemoglobin (A1C) levels. The Omnipod insulin system is a patch pump that consists of a handheld controller and disposable pod that delivers insulin. A retrospective analysis of medical records in the United States found that there was a significant reduction in A1C three months after initiating Omnipod in pediatric, adolescent and adult populations with T1D who switched from either MDI or traditional CSII. Currently, the real-world effectiveness of the Omnipod compared to MDI in adults with T1D on glycemic control, weight, and insulin dose, is not established.

The Canadian Real-World Outcomes of Omnipod Initiation in People with T1D: Evidence from the LMC Diabetes Registry (COPPER) study is a retrospective, observational study using demographic and clinical data from the LMC Diabetes Registry, which consists of over 42,000 active patients with diabetes across 3 Canadian provinces. The overall objectives of this study are to assess clinical outcomes in adults with T1D who switch from MDI to CSII therapy with Omnipod, and to compare clinical outcomes in the Omnipod cohort to a matched cohort of MDI users.
Experimental: Intervention group Intervention group: Home visit, health education, telephone counseling At the intervention group; the researcher firstly made spirometry meausurement in hospital. After, the researcher made pretest (baseline measurement) before nursing interventions at the first home visit. At the first home visit, the researcher was offered education and guide smoking cessation. Second, Third and fourth home visit were made 15 days later, one and six months after visit first visit. During the second, third and fourth home visits, firstly the patient's stage of change was determined and then appropriate nursing intervention was performed in accordance with the guidelines.Between the third and fourth home visits, the participants were contacted through telephone calls once a month. At fourth home visit, the researcher made posttest. After the patient was invited to the hospital and spirometry measurements were repeated.
Inflammatory bowel disease (IBD) is believed to be caused by various factors, including abnormalities in disease susceptibility genes, environmental factors, immune factors, and intestinal bacteria. Proton pump inhibitors (PPIs) are the primary drugs used to treat acid-related diseases. They are also commonly prescribed to patients with IBD. Recent studies have suggested a potential association between the use of certain medications, such as PPIs, and the occurrence and progression of IBD. In this review, we summarize the potential impact of PPIs on IBD and analyze the underlying mechanisms. Our findings may provide insights for conducting further investigations into the effects of PPIs on IBD and serve as an important reminder for physicians to exercise caution when prescribing PPIs to patients with IBD.
Carcinogenicity studies have not been conducted with fam-trastuzumab deruxtecan-nxki.

The topoisomerase inhibitor component of fam-trastuzumab deruxtecan-nxki, DXd, was clastogenic in both an in vivo rat bone marrow micronucleus assay and an in vitro Chinese hamster lung chromosome aberration assay and was not mutagenic in an in vitro bacterial reverse mutation assay.

Fertility studies have not been conducted with fam-trastuzumab deruxtecan-nxki. In a six-week repeat-dose toxicity study in rats, intravenous administration of fam-trastuzumab deruxtecan-nxki resulted in spermatid retention at 20 mg/kg and 60 mg/kg (approximately 4 and 9 times the human recommended dose of 5.4 mg/kg based on AUC, respectively). Decreased testes and epididymides weights, tubular atrophy/degeneration in testes, and reduced sperm count in epididymides were observed at a dose of 197 mg/kg (19 times the human recommended dose of 5.4 mg/kg based on AUC). In a three-month repeat-dose toxicity study in monkeys, intravenous administration of fam-trastuzumab deruxtecan-nxki resulted in decreased numbers of round spermatids in the testes at seminiferous tubule stages V to VI at ≥30 mg/kg (≥7 times the human recommended dose of 5.4 mg/kg based on AUC). Evidence of reversibility was observed in monkeys by the end of a three-month recovery period.
This invention refers to food and pharmaceutical industry.    The method comprises extracting tea raw, tea crumb, beet pulp of the concentrate production wastes or tea dust by hot water,squeezing residues, drying the beet pulp up to humidity 10-12% in the drum drier.    The raw is gridded, the soya oil is added to the proportion of 1:5 to 1:12.    The product is mixed at a temperature of 70-850C during 30-60 minutes, then standing during 3-4 hours, extracting by organic solvent, the solvent being driven off. The yield of the concentrate is 82.9 kg/t, the tocopherol being to 0,375 kg/t,pigments-to 0,870 kg/t in respect of raw .    1 table